Search by intervention, mechanism or outcome. Ratings describe the evidence for each dimension; they are not a shopping score.
Modest symptom or appearance benefits are plausible; this is not an anti-ageing intervention in the broad sense.
Useful evidence for strength and training support; longevity benefits would be indirect.
Small human studies are intriguing, but the claims currently outrun the sample sizes.
Useful as part of protein strategy in selected older adults; isolated leucine is not a longevity treatment.
Physiologically essential, clinically useful in defined situations, and chronically over-marketed.
Established clinical uses do not automatically translate into routine longevity benefit.
Biologically active and well studied for NAD elevation; clinical outcome evidence is thin.
Raises NAD-related biomarkers; broad healthspan benefits have not followed reliably.
Some cardiovascular effects are real, but formulation, dose and baseline risk matter greatly.
Exceptional animal lifespan evidence; no proof of human life extension and meaningful clinical risks.
Compelling animal ageing biology; human longevity claims remain untested.
A plausible mitophagy intervention with early functional signals, still far from longevity proof.
Important when deficient; extra supplementation is not a universal longevity multiplier.
Biologically relevant to clotting and bone proteins; routine anti-calcification claims exceed the trial evidence.